Clinical trials · North Carolina
Metastatic Prostate Cancer clinical trials in North Carolina
We’re tracking 53 recruiting metastatic prostate cancer studies with a site in North Carolina — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in North Carolina
- NCT07028853RecruitingPhase 3
New drug combo for advanced prostate cancer
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
Cary, North CarolinaAges 18 years+ - NCT06067841RecruitingPhase 1
New drug for advanced prostate cancer
This study tests a new drug (BMS-986460) for people with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the drug can shrink or slow the cancer.
Durham, North CarolinaAges 18 years+ - NCT06134232RecruitingPhase 2
Extra sipuleucel-T after Provenge for prostate cancer
This trial tests whether adding one extra infusion of sipuleucel-T (the same drug as Provenge) after the standard three doses can help men with advanced prostate cancer that no longer responds to hormone therapy. It is for men who have already finished their three Provenge infusions and have mild or no symptoms.
Raleigh, North CarolinaAges 18 years+ - NCT04986423RecruitingPhase 2
Add ZEN003694 to enzalutamide for resistant prostate cancer
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
Asheville, North CarolinaAges 18 years+ - NCT05125016RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer after standard treatments
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
Charlotte, North CarolinaAges 18 years+ - NCT06228053RecruitingPhase 2
Study of SX-682 plus enzalutamide for men with advanced prostate cancer
This trial tests whether adding the drug SX-682 to enzalutamide can help men whose prostate cancer has stopped responding to other hormone treatments. You may be eligible if your cancer is growing despite treatment with abiraterone, darolutamide, apalutamide, or enzalutamide.
Durham, North CarolinaAges 18 years+ - NCT07164443RecruitingPhase 3
Study comparing pasritamig to placebo for advanced prostate cancer
This trial tests a new drug called pasritamig against a placebo for people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. The goal is to see if pasritamig can help slow the cancer's growth.
Charlotte, North CarolinaAges 18 years+ - NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Durham, North CarolinaAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Chapel Hill, North CarolinaAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Chapel Hill, North CarolinaAges 18 years+ - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
Durham, North CarolinaAges 18 years+ - NCT05011383RecruitingPhase 2
High dose testosterone for prostate cancer with ATM, CDK12, or CHEK2 changes
This trial is testing whether high doses of testosterone can help treat advanced prostate cancer in men who have a specific genetic change (ATM, CDK12, or CHEK2). It is for patients whose cancer has stopped responding to current hormone therapies.
Durham, North CarolinaAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Durham, North CarolinaAges 18–130 - NCT03151629Recruiting
Registry for men with advanced prostate cancer
This study is a worldwide registry that collects health information from men with advanced prostate cancer. It may help researchers better understand disease patterns and outcomes, which can guide future treatments.
Durham, North CarolinaAges 21 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Chapel Hill, North CarolinaAges Any age - NCT03678025RecruitingPhase 3
Standard treatment for metastatic prostate cancer, with or without local treatment
This Phase 3 trial studies whether using the usual medicines for metastatic prostate cancer, plus a definitive local treatment to the prostate, improves outcomes. It may help determine if treating the prostate directly can benefit people whose cancer has not worsened after initial hormone-based treatment.
Concord, North CarolinaAges 18 years+ - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Charlotte, North CarolinaAges 18 years+ - NCT04038502RecruitingPhase 2
Testing carboplatin or olaparib for gene-linked prostate cancer
This Phase 2 study tests whether carboplatin or olaparib can help people with prostate cancer that has certain DNA repair gene changes. It’s designed for advanced (metastatic) prostate cancer that is growing despite standard hormone-blocking treatment.
Durham, North CarolinaAges 18 years+ - NCT04221542RecruitingPhase 1
AMG 509 for advanced, hormone-resistant prostate cancer
This trial tests AMG 509, a study drug, in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite lowering testosterone). It’s for people whose cancer has progressed after certain hormone tablets and possibly chemotherapy, aiming to shrink tumors and control the disease safely.
Durham, North CarolinaAges 18 years+ - NCT04423211RecruitingPhase 3
Surgery-recovered prostate cancer treated with PET-guided radiation
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
Kenansville, North CarolinaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Durham, North CarolinaAges 12 years+ - NCT04729114RecruitingPhase 1
Safety and dose test of PRL-02 shot for advanced prostate cancer
This Phase 1 study tests how safe PRL-02 depot (an injection) is and finds the best dose for men with advanced prostate cancer. It may help determine a new treatment option for cancers that have spread or are getting worse despite standard care.
Durham, North CarolinaAges 18 years+ - NCT04787744RecruitingPhase 2/Phase 3
Test standard prostate cancer treatment with or without targeted spot radiation
This study tests whether adding targeted local treatment (like radiation to a few spots seen on scans) improves outcomes for some people with limited (oligometastatic) prostate cancer. It compares standard systemic therapy alone versus standard therapy plus PET-scan–guided spot treatment.
Durham, North CarolinaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Chapel Hill, North CarolinaAges 18 years+
Metastatic Prostate Cancer trials by city in North Carolina
Where these studies are running in North Carolina
Institutions with a site for the recruiting metastatic prostate cancer studies listed above.
- Duke University · 5 studies
- Durham VA Medical Center · 5 studies
- Levine Cancer Institute · 4 studies
- Duke University Medical Center · 3 studies
- Atrium Health Cabarrus · 2 studies
- Atrium Health Union · 2 studies
- Atrium Health University City · 2 studies
- Carolinas Medical Center/Levine Cancer Institute · 2 studies
What taking part in a metastatic prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Prostate Cancer trials in other states
Common questions
- Are there metastatic prostate cancer clinical trials in North Carolina?
- Yes. We're currently tracking 53 recruiting metastatic prostate cancer studies with a site in North Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic prostate cancer study in North Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in North Carolina to take part?
- Not necessarily. These studies have a site in North Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic prostate cancer studies open in North Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.